Immunotherapy: The Meta-Analyses. What have we Learned?

被引：27

作者：

Calderon, Moises A. ^{[1
]}

Boyle, Robert J. ^{[3
]}

Penagos, Martin ^{[2
]}

Sheikh, Aziz ^{[4
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Dept Allergy & Resp Med, Natl Heart & Lung Inst, Royal Brompton & Harefield Trust, London SW3 6LY, England

[2] St Thomas Hosp, Dept Paediat Allergy, London SE1 7EH, England

[3] Univ London Imperial Coll Sci Technol & Med, Dept Paediat, St Marys Hosp, London W2 1PG, England

[4] Univ Edinburgh, Allergy & Resp Res Grp, Ctr Populat Hlth Sci, Sch Med, Edinburgh EH8 9AG, Midlothian, Scotland

来源：

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA | 2011年 / 31卷 / 02期

关键词：

Specific allergen immunotherapy; Meta-analysis; Rhinitis; Asthma; SUBLINGUAL IMMUNOTHERAPY; ALLERGIC RHINITIS; RESPIRATORY ALLERGY; DOUBLE-BLIND; PEDIATRIC-PATIENTS; METAANALYSIS; EFFICACY; ASTHMA; DISEASES; CHILDREN;

D O I：

10.1016/j.iac.2011.02.002

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Meta-analysis is a powerful tool for evaluating the efficacy of a therapeutic intervention, and has clearly demonstrated that specific allergen immunotherapy (SIT) is effective for treating allergic rhinitis and asthma. Future research needs to focus on specifying the most effective forms of SIT for specific populations and allergens, using validated clinical outcomes, studying long-term outcomes (particularly the potential disease-modifying effect of immunotherapy), and assessing outcomes regarding health economics. The safety profile of SIT should be evaluated using international guidelines and terminology, and needs to include high-quality surveillance data.

引用

页码：159 / +

页数：16

共 50 条

[41] HIV: what have we learned?
Kralik, Debbie
[J]. JOURNAL OF ADVANCED NURSING, 2010, 66 (02) : 245 - 245
[42] MAINSTREAMING - WHAT HAVE WE LEARNED
ALLEN, KE
[J]. YOUNG CHILDREN, 1980, 35 (05): : 54 - 63
[43] MOOCS: What Have We Learned?
Koller, Daphne
[J]. KDD'15: PROCEEDINGS OF THE 21ST ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, 2015, : 3 - 3
[44] IMRT, what have we learned?
Mast, M.
Wiggenraad, R.
Struikmans, H.
[J]. RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S121 - S121
[45] Myeloma: what have we learned?
Bergsagel, DE
[J]. BIOMEDICINE & PHARMACOTHERAPY, 2001, 55 (9-10) : 548 - 549
[46] Arthroereisis What Have We Learned?
Ortiz, Cristian A.
Wagner, Emilio A.
Wagner, Pablo A.
[J]. FOOT AND ANKLE CLINICS, 2018, 23 (03) : 415 - +
[47] IMAGES - what we have learned
Lees, KR
[J]. STROKE, 2004, 35 (06) : E185 - E185
[48] So what have we learned?
Elston, H. J.
[J]. JOURNAL OF CHEMICAL HEALTH & SAFETY, 2010, 17 (01): : 3 - 3
[49] Then and Now: What Have We Learned?
Rapoport, David C.
[J]. TERRORISM AND POLITICAL VIOLENCE, 2001, 13 (03) : XI - +
[50] Telemedicine What have we learned?
Whitten, P.
Holtz, B.
LaPlante, C.
[J]. APPLIED CLINICAL INFORMATICS, 2010, 1 (02): : 132 - 141

← 1 2 3 4 5 →